Interleukin‐2 deprived state of regulatory T cells and their recovery by low‐dose interleukin‐2 in patients with inflammatory myopathies
Objective Regeneration and expansion of regulatory T cells (Treg) by low‐dose interleukin‐2 (IL‐2) therapy is considered a potential treatment strategy for a wide range of autoimmune diseases. To provide a pathophysiologically‐based rationale for low‐dose IL‐2 therapy, we invest…